drugset / Trial / NCT06208410
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is an open-label, multicenter, Phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JS105 in combination with other anti-tumor therapies in patients with advanced solid tumors. Patients will be enrolled in two stages: a dose-escalation stage and a dose-expansion stage.
Timeline
- Start
- 2024-01-11
- Primary completion
- 2027-02-26
- Completion
- 2027-02-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | Oral |
| Subject | Dalpiciclib | Small molecule | — | Oral |
| Subject | Fluzoparib | Small molecule | — | Oral |
| Subject | Fulvestrant | Small molecule | — | Intramuscular |
| Subject | JS105 | Unknown | — | Oral |
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Subject | Pyrotinib | Small molecule | — | Oral |
| Subject | Toripalimab | Monoclonal antibody | — | Intravenous |